Is a complete IMVT research report available?

No complete published report is available for Immunovant, Inc. (IMVT) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Immunovant, Inc. (IMVT)

NASDAQ: IMVT · USD

$38.6

-0.29 (-0.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IMVT analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	8B
Net income (ttm)	-505.6M
EPS (ttm)	-$2.77
Shares out	206.4M
Volume	1,620,326
Beta	0.77
Price target	$47.5	+23.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -505.6M
EPS (ttm): -$2.77
Market cap: 8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IMVT indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001764013
Company name	Immunovant, Inc.
Country	United States
Country code	US
Cusip	45258J102
Employees	315
Employees Change	-47%
Employees Change Percent	-12.98
Enterprise value	$7.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US45258J1025
Last refreshed	2026-07-30
Market cap	$8B
Market cap category	Mid-Cap
Price	$38.61
Price currency	USD
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	2836
Symbol	IMVT
Website	https://immunovant.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.34%
FCF yield	-5.11%
P/B ratio	9.24x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-505.6M
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROA	-38.43
Roa5y	-31.43
ROCE	-62.5
ROE	-64.82
Roe5y	-53.46
ROIC	-42.69

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	130.5%
Cagr3y	19.66%
Cagr5y	29.05%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$957M
Cash	$902.1M
Current Assets	$948.8M
Current Liabilities	$104.4M
Debt	$72,000
Debt Equity	$0
Equity	$852.6M
Liabilities	$104.4M
Long Term Assets	$8.2M
Long Term Liabilities	$0
Net Cash	$902M
Net Cash By Market Cap	$11.32
Net Cash Growth	26.36%
Net Debt Equity	$-1.06
Tangible Book Value	$852.6M
Tangible Book Value Per Share	$4.18
WACC	8.46

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.09
Net Working Capital	$-57.6M
Quick ratio	8.68
Working Capital	$844.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-20.35%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	130.37%
200-day SMA	27.84
3Y total return	71.37%
50-day SMA	36.06
50-day SMA vs 200-day SMA	50over200
5Y total return	257.83%
All Time High	53.75
All Time High Change	-28.17%
All Time High Date	2020-11-18
All Time Low	3.15
All Time Low Change	1,127.66%
All Time Low Date	2022-06-13
ATR	1.49
Beta	0.77
Beta1y	1.34
Beta2y	1.01
Ch YTD	51.89
High	39.41
High52	41.23
High52 Date	2026-07-09
High52ch	-6.35%
Low	37.75
Low52	14.32
Low52 Date	2025-08-11
Low52ch	169.62%
Ma50ch	7.08%
Premarket Change Percent	0.36
Premarket Price	$39.04
Premarket Volume	146,531
Price vs 200-day SMA	38.7%
RSI	51.9
RSI Monthly	69.41
RSI Weekly	67.49
Sharpe ratio	1.58x
Sortino ratio	3.51
Total Return	-20.35%
Tr YTD	51.89
Tr1m	-0.62%
Tr1w	-1.13%
Tr3m	43.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	16
Analyst Count Top	13
Analyst Price Target Top	$47.54
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.52
Operating Income	$-532.9M
Price target	$47.53
Price Target Change	$23.1
Price Target Change Top	$23.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	79,786,279%
Float Percent	38.66%
Shares Insiders	0.86%
Shares Institutions	48.05%
Shares Out	206,402,338
Shares Qo Q	12.23%
Shares Yo Y	20.35%
Short Float	22.26%
Short Ratio	11.24
Short Shares	8.6

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-463M
Adjusted OCF	-463,034,000
Average Volume	1,014,621.75x
Bv Per Share	4.18
CAPEX	$-8,000
Ch1m	-0.62
Ch1w	-1.13
Ch1y	130.4
Ch3m	43.05
Ch3y	71.37
Ch5y	257.8
Ch6m	48.16
Change	-0.75%
Change From Open	-0.95
Close	38.9
Days Gap	0.21
Depreciation Amortization	409,000
Dollar Volume	62,560,786.9
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-532.9M
EBITDA	$-532.5M
EPS	$-2.77
F Score	1
FCF	$-407.3M
FCF EV Yield	-5.76x
FCF Per Share	$-1.97
Financing CF	595,756,000
Fiscal Year End	March
Founded	2,018
Income Tax	$215,000
Investing CF	-8,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-20
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-05-20
Ma150	29.6
Ma150ch	30.43%
Ma20	39.41
Ma20ch	-2.03%
Net CF	188,139,000
Next Earnings Date	2026-08-06
Open	38.98
Optionable	Yes
Position In Range	51.81
Post Close	38.61
Postmarket Change Percent	-1.55
Postmarket Price	$38.01
Ppne	515,000
Pre Close	38.9
Price Date	2026-07-29
Ptbv Ratio	9.35
Relative Volume	1.6x
Share Based Comp	55,724,000
Tr6m	48.16%
Us State	North Carolina
Volume	1,620,326

Immunovant, Inc. (IMVT)

Coverage state: Market snapshot only — no published research

Generate the first IMVT analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IMVT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMVT indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IMVT

Frequently asked questions